Last reviewed · How we verify
NCT05411276
A Real-World Study of Pyrotinib Maleate in the Treatment of Advanced/Metastatic Non-Small Cell Lung Cancer With Rare Mutations in HER2
trial testing Pyrotinib maleate in HER2 Mutant Non-small Cell Lung Cancer in 15 participants. Status unknown.
31 December 2023
Quick facts
| Lead sponsor | Beijing Chest Hospital |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 15 |
| Start date | 30 June 2022 |
| Primary completion | 31 December 2023 |
| Estimated completion | 31 December 2024 |
Drugs / interventions tested
- Pyrotinib maleate
Conditions studied
- HER2 Mutant Non-small Cell Lung Cancer — all drugs for HER2 Mutant Non-small Cell Lung Cancer →
Sponsor
Beijing Chest Hospital
Who can join
Adults 18 to 70, any sex, with HER2 Mutant Non-small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
At present, the main characteristics of the enrolled population in the clinical study of HER2-mutated non-small cell lung cancer are the YVMA mutation type. There are no relevant clinical trials specifically targeting rare mutation types. Pyrotinib has been approved for the treatment of HER2-positive advanced breast cancer in China, and pyrotinib has shown good development prospects in the treatment of advanced non-small cell lung cancer. The purpose of this study is to observe the efficacy and safety of pyrotinib maleate in patients with HER2 rare mutation in advanced non-small cell lung cancer.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Targeted therapies in non-small cell lung cancer: present and future.
McLaughlin J, Berkman J, Nana-Sinkam P. · · 2023 · cited 11× · PMID 37675274 · DOI 10.12703/r/12-22
Verify or expand the search:
- PubMed search for NCT05411276
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Pyrotinib maleate
Trials testing the same drug.
- NCT05426486 — A Study of ARX788 Combined With Pyrotinib Maleate Versus TCBHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplat · Phase 2, PHASE3 · active not recruiting
Other Beijing Chest Hospital trials
Trials by the same sponsor.
- NCT07372781 — Clinical Study on the Early Bactericidal Activity of Contezolid Against Mycobacterium Abscessus Disease · Phase 2 · enrolling by invitation
- NCT07268664 — Innovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis：BLMZ Chinese Cohort · Phase 3 · not yet recruiting
- NCT06809413 — Clinical Study on the Early Bactericidal Activity of Sitafloxacin Against Mycobacterium Abscessus Disease · Phase 2 · enrolling by invitation
- NCT06764368 — Phase II Study of Adebrelimab, Chemotherapy, and Apatinib for Advanced Pulmonary Neuroendocrine Tumors · Phase 2 · not yet recruiting
- NCT06811025 — Phase II Clinical Study of Contezolid for the Treatment of Tuberculous Meningitis · Phase 1, PHASE2 · enrolling by invitation
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05411276 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Beijing Chest Hospital
- Last refreshed: 9 June 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05411276.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing